Relative contribution of il-1α, il-1β and tnf to the host response to mycobacterium tuberculosis and attenuated m. Bovis bcg

Immunity, Inflammation and Disease

Volumn 1, Issue 1, 2013, Pages 47-62

  Bourigault, Marie Laure ^a,b   Segueni, Noria ^a,b   Rose, Stephanie ^a,b   Court, Nathalie ^a,b   Vacher, Rachel ^a,b   Vasseur, Virginie ^a,b   Erard, François ^a,b   Bert, Marc Le ^a,b   Garcia, Irene ^c   Iwakura, Yoichiro ^d   Jacobs, Muazzam ^e,f   Ryffel, Bernhard ^a,b,e   Quesniaux, Valerie F J ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Bovis infection; Host response; IL 1 IL 1 ; M; TNF; Tuberculosis

Indexed keywords

EID: 84929084052     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.9     Document Type: Article

References (60)

1. Dye, C. C. J. Watt, D. M. Bleed, S. M. Hosseini, and M. C. Raviglione. 2005. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293:2767–2775.
2. Dye C. and B. G. Williams. The population dynamics and control of tuberculosis. Science 328:856–861.
3. Gill, W. P. N. S. Harik, M. R. Whiddon, R. P. Liao, J. E. Mittler, and D. R. Sherman. 2009. A replication clock for Mycobacterium tuberculosis. Nat. Med. 15:211–214.
4. Keane. J. 2005. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44:714–720.
5. Keane, J. S. Gershon, R. P. Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, J. N. Siegel, and M. M. Braun. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098–1104.
6. Mohan, A. K. T. R. Cote, J. N. Siegel, and M. M. Braun. 2003. Infectious complications of biologic treatments of rheumatoid arthritis. Curr. Opin. Rheumatol. 15:179–184.
7. Mohan, V. P., C. A. Scanga, K. Yu, H. M. Scott, K. E. Tanaka, E. Tsang, M. M. Tsai, J. L. Flynn, and J. Chan. 2001. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69:1847–1855.
8. Tubach, F. D. Salmon, P. Ravaud, Y. Allanore, P. Goupille, M. Breban, B. Pallot-Prades, S. Pouplin, A. Sacchi, R. M. Chichemanian, et al. 2009. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60:1884–1894.
9. Dinarello, C. A. A. Simon, and J. W. van der Meer. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11:633–652.
10. Sugawara, I. H. Yamada, S. Hua, and S. Mizuno. 2001. Role of interleukin (IL)-1 type 1 receptor in mycobacterial infection. Microbiol. Immunol. 45:743–750.
11. Juffermans, N. P. S. Florquin, L. Camoglio, A. Verbon, A. H. Kolk, P. Speelman, S. J. van Deventer, and T. van Der Poll. 2000. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 182:902–908.
12. Yamada, H. S. Mizumo, R. Horai, Y. Iwakura, and I. Sugawara. 2000. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Invest. 80:759–767.
13. Fremond, C. M. D. Togbe, E. Doz, S. Rose, V. Vasseur, I. Maillet, M. Jacobs, B. Ryffel, and V. F. Quesniaux. 2007. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J. Immunol. 179:1178–1189.
14. Master, S. S. S. K. Rampini, A. S. Davis, C. Keller, S. Ehlers, B. Springer, G. S. Timmins, P. Sander, and V. Deretic. 2008. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe. 3:224–232.
15. Mayer-Barber, K. D. D. L. Barber, K. Shenderov, S. D. White, M. S. Wilson, A. Cheever, D. Kugler, S. Hieny, P. Caspar, G. Nunez, et al. 2010. Caspase-1 independent IL-1beta production is critical for host resistance to Mycobacterium tuberculosis and does not require TLR signaling in vivo. J. Immunol. 184:3326–3330.
16. Mayer-Barber, K. D. B. B. Andrade, D. L. Barber, S. Hieny, C. G. Feng, P. Caspar, S. Oland, S. Gordon, and A. Sher. 2011. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35:1023–1034.
17. Flynn J. L. and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93–129.
18. Flynn. J. L. 2004. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84:93– 101.
19. North R. J. and Y. J. Jung. 2004. Immunity to tuberculosis. Annu. Rev. Immunol. 22:599–623.
20. Korbel, D. S. B. E. Schneider, and U. E. Schaible. 2008. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 10:995–1004.
21. Mishra, B. B, V. A. Rathinam, G. W. Martens, A. J. Martinot, H. Kornfeld, K. A. Fitzgerald, and C. M. Sassetti. 2013. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat. Immunol. 14:52–60.
22. Settas, L. D. G. Tsimirikas, G. Vosvotekas, E. Triantafyllidou, and P. Nicolaides. 2007. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J. Clin. Rheumatol. 13:219–220.
23. Botsios, C. P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, and L. Punzi. 2007. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis. Reumatismo 59:32–37.
24. Alten, R. H. Gram, L. A. Joosten, W. B. van den Berg, J. Sieper, S. Wassenberg, G. Burmester, P. van Riel, M. Diaz-Lorente, G. J. Bruin, et al. 2008. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10:R67.
25. Lachmann, H. J. I. Kone-Paut, J. B. Kuemmerle-Deschner, K. S. Leslie, E. Hachulla, P. Quartier, X. Gitton, A. Widmer, N. Patel, and P. N. Hawkins. 2009. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360:2416–2425.
26. Owyang, A. M. H. Issafras, J. Corbin, K. Ahluwalia, P. Larsen, E. Pongo, M. Handa, A. H. Horwitz, M. K. Roell, M. Haak-Frendscho, et al. 2011. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs. 3:49–60.
27. Wilkinson, R. J. P. Patel, M. Llewelyn, C. S. Hirsch, G. Pasvol, G. Snounou, R. N. Davidson, and Z. Toossi. 1999. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J. Exp. Med. 189:1863–1874.
28. Gomez, L. M. J. F. Camargo, J. Castiblanco, E. A. Ruiz-Narvaez, J. Cadena, and J. M. Anaya. 2006. Analysis of IL1B, TAP1, TAP2 and IKBL polymorphisms on susceptibility to tuberculosis. Tissue Antigens 67:290–296.
29. Motsinger-Reif, A. A. P. R. Antas, N. O. Oki, S. Levy, S. M. Holland, and T. R. Sterling. 2010. Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med. Genet. 11:37.
30. Guler, R. S. P. Parihar, G. Spohn, P. Johansen, F. Brombacher, and M. F. Bachmann. 2011. Blocking IL-1alpha but not IL-1beta increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 29:1339–1346.
31. McElvania Tekippe, E. I. C. Allen, P. D. Hulseberg, J. T. Sullivan, J. R. McCann, M. Sandor, M. Braunstein, and J. P. Ting. 2010. Granuloma formation and host defense in chronic Mycobacterium tuberculosis infection requires PY-CARD/ASC but not NLRP3 or caspase-1. PLoS ONE 5: e12320.
32. Walter, K. C. Holscher, J. Tschopp, and S. Ehlers. 2010. NALP3 is not necessary for early protection against experimental tuberculosis. Immunobiology 215:804–811.
33. Mishra, B. B. P. Moura-Alves, A. Sonawane, N. Hacohen, G. Griffiths, L. F. Moita, and E. Anes. 2010. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol. 12:1046– 1063.
34. Abdalla, H. L. Srinivasan, S. Shah, K. D. Mayer-Barber, A. Sher, F. S. Sutterwala, and V. Briken. 2012. Mycobacterium tuberculosis infection of dendritic cells leads to partially caspase-1/11-independent IL-1beta and IL-18 secretion but not to pyroptosis. PLoS ONE 7:e40722.
35. Horai, R. M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, and Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187:1463– 1475.
36. Gross, O. C. J. Thomas, G. Guarda, and J. Tschopp. 2011. The inflammasome: an integrated view. Immunol. Rev. 243:136– 151.
37. Fettelschoss, A. M. Kistowska, S. LeibundGut-Landmann, H. D. Beer, P. Johansen, G. Senti, E. Contassot, M. F. Bachmann, L. E. French, A. Oxenius, et al. 2011. Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc. Natl. Acad. Sci. USA 108:18055–18060.
38. Jayaraman, P. I. Sada-Ovalle, T. Nishimura, A. C. Anderson, V. K. Kuchroo, H. G. Remold, and S. M. Behar. 2013. IL-1beta promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation. J. Immunol. 190:4196–4204.
39. Bean, A. G. D. R. Roach, H. Briscoe, M. P. France, H. Korner, J. D. Sedgwick, and W. J. Britton. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504–3511.
40. Kaneko H., H. Yamada, S. Mizuno, T. Udagawa, Y. Kazumi, K. Sekikawa, and I. Sugawara. 1999. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest. 79:379–386.
41. Roach, D. R. A. G. Bean, C. Demangel, M. P. France, H. Briscoe, and W. J. Britton. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168:4620–4627.
42. Fremond, C. N. Allie, I. Dambuza, S. I. Grivennikov, V. Yeremeev, V. F. Quesniaux, M. Jacobs, and B. Ryffel. 2005. Membrane TNF confers protection to acute mycobacterial infection. Respir. Res. 6:136.
43. Muller, M. H. P. Eugster, M. Le Hir, A. Shakhov, F. Di Padova, C. Maurer, V. F. Quesniaux, and B. Ryffel. 1996. Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation. Mol. Med. 2:247–255.
44. Fremond, C. M. V. Yeremeev, D. M. Nicolle, M. Jacobs, V. F. Quesniaux, and B. Ryffel. 2004. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J. Clin. Invest. 114:1790–1799.
45. Olleros, M. L. D. Vesin, R. Bisig, M. L. Santiago-Raber, S. Schuepbach-Mallepell, G. Kollias, O. Gaide, and I. Garcia. 2012. Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules. PLoS ONE 7:e31469.
46. Jacobs, M. N. Brown, N. Allie, and B. Ryffel. 2000. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin. Immunol. 94:192–199.
47. Jacobs, M. M. W. Marino, N. Brown, B. Abel, L. G. Bekker, V. J. Quesniaux, L. Fick, and B. Ryffel. 2000. Correction of defective host response to Mycobacterium bovis BCG infection in TNF-deficient mice by bone marrow transplantation. Lab Invest. 80:901–914.
48. Feng, C. G. C. A. Scanga, C. M. Collazo-Custodio, A. W. Cheever, S. Hieny, P. Caspar, and A. Sher. 2003. Mice lacking myeloid differentiation factor 88 display profound defects in host resistance and immune responses to Mycobacterium avium infection not exhibited by Toll-like receptor 2 (TLR2)-and TLR4-deficient animals. J. Immunol. 171:4758–4764.
49. Holscher, C. N. Reiling, U. E. Schaible, A. Holscher, C. Bathmann, D. Korbel, I. Lenz, T. Sonntag, S. Kroger, S. Akira, et al. 2008. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2,-4 and-9. Eur. J. Immunol. 38:680–694.
50. Nicolle, D. M. X. Pichon, A. Bouchot, I. Maillet, F. Erard, S. Akira, B. Ryffel, and V. F. Quesniaux. 2004. Chronic pneumonia despite adaptive immune response to Mycobacterium bovis BCG in MyD88-deficient mice. Lab Invest. 84:1305–1321.
51. Sugawara, I. H. Yamada, S. Mizuno, K. Takeda, and S. Akira. 2003. Mycobacterial infection in MyD88-deficient mice. Microbiol. Immunol. 47:841–847.
52. Fleischmann, R. M., J. Tesser, M. H. Schiff, J. Schechtman, G. R. Burmester, R. Bennett, D. Modafferi, L. Zhou, D. Bell, and B. Appleton. 2006. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65:1006–1012.
53. Nicolle, D. C. Fremond, X. Pichon, A. Bouchot, I. Maillet, B. Ryffel, and V. J. Quesniaux. 2004. Long-term control of Mycobacterium bovis BCG infection in the absence of Toll-like receptors (TLRs): investigation of TLR2-, TLR6-, or TLR2-TLR4-deficient mice. Infect. Immun. 72:6994–7004.
54. Sander, L. E. M. J. Davis, M. V. Boekschoten, D. Amsen, C. C. Dascher, B. Ryffel, J. A. Swanson, M. Muller, and J. M. Blander. 2011. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 474:385– 389.
55. Court, N. V. Vasseur, R. Vacher, C. Fremond, Y. Shebzukhov, V. V. Yeremeev, I. Maillet, S. A. Nedospasov, S. Gordon, P. G. Fallon, et al. 2010. Partial redundancy of the pattern recognition receptors, scavenger receptors, and C-type lectins for the long-term control of Mycobacterium tuberculosis infection. J. Immunol. 184:7057–7070.
56. Gringhuis, S. I. T. M. Kaptein, B. A. Wevers, B. Theelen, M. van der Vlist, T. Boekhout, and T. B. Geijtenbeek. 2012. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat. Immunol. 13:246–254.
57. Novikov, A. M. Cardone, R. Thompson, K. Shenderov, K. D. Kirschman, K. D. Mayer-Barber, T. G. Myers, R. L. Rabin, G. Trinchieri, A. Sher, et al. 2011. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J. Immunol. 187:2540– 2547.
58. Allie, N. S. I. Grivennikov, R. Keeton, N.-J. Hsu, M.-L. Bourigault, N. Court, C. Fremond, V. Yeremeev, Y. Shebzukhov, B. Ryffel, et al. 2013. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci. Rep. 3:1809.
59. Labow, M. D. Shuster, M. Zetterstrom, P. Nunes, R. Terry, E. B. Cullinan, T. Bartfai, C. Solorzano, L. L. Moldawer, R. Chizzonite, et al. 1997. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J. Immunol. 159:2452–2461.
60. Marino, M. W, A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94:8093–8098.